PATENT CLAIM ANALYSIS

Application Number: 16149522
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-01
Patent Classification: ["514", "210180"]

Abstract:
The problem to be solved by the present invention is to provide an anticancer agent for treating tumors resistant to other antitumor agents that inhibit FGFR, and a method for treating such tumors. The present invention provides an antitumor agent for administration to a tumor patient resistant to an FGFR inhibitor, the antitumor agent comprising a 3,5-disubstituted benzene alkynyl compound represented by Formula (I) below or a salt thereof. The present invention also provides a therapeutic method using the anticancer agent.

Claim (Index 2):
The antitumor agent according to  claim 1  for administration to a tumor patient resistant to at least one of ponatinib, regorafenib, intedanib, dovitinib lactate, lenvatinib mesylate, cediranib, oratinib, brivanib alaninate, AZD4547, NVP-BGJ398, sulfatinib, ARQ-087, S-49076, IMCA1, PRO001, and R3Mab.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 97.0
- Lexical Diversity: 1.69231
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14905047', '13859569', '14344935', '15575448', '13617035']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.757722508189213
- 35 USC 102 Novelty (BERT): 0.616898763975483
- Combined Prediction Score: 0.7436401337678401
- Mean Citation Score: 361.98346
- Max Citation Score: 551.84607
- Similarity Product: 492.7551259765257

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test